Pancreatic Cancer Market Players:
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG Pfizer Inc.
- Aduro Biotech Inc.
- Clovis Oncology Inc.
- NewLink Genetics Corp
- Infinity Pharmaceuticals, Inc.
- Celgene Corporation
- Novocure
- AIM ImmunoTech Inc.
The market is propagating with the continuous R&D activity and cohort, led by key players. They are investing heavily in developing new treatment alternatives with higher response rates and survival possibilities. For instance, in December 2024, NANOBIOTIX shared updates from the phase I trial on radiotherapy-activated NBTXR3 (JNJ-1900), treating patients with locally advanced pancreatic cancer or borderline resectable pancreatic cancer. They revealed the completion of the dose escalation and dose expansion parts of this evaluation process, conducted by The University of Texas MD Anderson Cancer Center. These research initiatives further inspire more companies to participate in this field. Such key players are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of pancreatic cancer is assessed at USD 3.69 billion.
The global pancreatic cancer market size was valued at over USD 3.28 billion in 2025 and is expected to register a CAGR of more than 13.9%, exceeding USD 12.05 billion revenue by 2035.
The North America pancreatic cancer market is expected to achieve a 32% share by 2035, fueled by increasing adoption of new technologies to deliver better cancer care and outcomes.
Key players in the market include Amgen Inc., Novartis AG Pfizer Inc., Aduro Biotech Inc., Clovis Oncology Inc., NewLink Genetics Corp, Infinity Pharmaceuticals, Inc., and Celgene Corporation.
